- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05961007
Evaluation of IBI302 Injection in nAMD or DME
July 17, 2023 updated by: Innovent Biologics (Suzhou) Co. Ltd.
A Dose Escalation Study to Evaluate the Safety and Tolerability of IBI302 Intravitreal Injection in Subjects With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema AND A Multi-center, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With Diabetic Macular Edema
The purpose of this study is to determine the efficacy and safety of intravitreal IBI302 in the treatment of subjects with neovascular age-related macular degeneration (only in Phase I) or diabetic macular edema.
Study Overview
Status
Suspended
Study Type
Interventional
Enrollment (Estimated)
234
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100044
- Peking University People's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion criteria
- Willing and able to sign informed consent form and comply with visit and study procedures per protocol;
- Male or female patiensubjects ≥ 18 yrs. of age;
- For AMD subjects, active subfoveal or parafoveal CNV secondary to neovascular AMD; the vision decreased by nAMD;
- For DME subjects, Type 1 or type 2 diabetes mellitus, decrease in vision determined to be primarily the result of DME in the study eye; the CST measurement of ≥ 280 μm in the study eye;
- BCVA ETDRS letter score of 24-73 in the study eye;
Exclusion criteria
- Concomitant diseases that may cause subjects fail to respond to the treatment or confuse the interpretation of the study results;
- Presence of uncontrolled glaucoma in the study eye ;
- Presence of active intraocular or periocular inflammation or infection;
Prior any treatment of following in the study eye:
- Anti-VEGF therapy or anti-complement therapy;
- Laser photocoagulation;
- History of vitreoretinal surgery;
- Glucocorticoid treatment(intravitreal or peribulbar) ;
- BCVA score <19 letters in the fellow eye;
- Anti-VEGF therapy in the fellow eye within 30 days of day 0;
- Presence of any systemic disease: including but not limited to active infections (such as active viral hepatitis); unstable angina; cerebrovascular accident or transient cerebral ischemia (within 6 months prior to screening); myocardial infarction (within 6 months prior to screening; serious arrhythmia requiring medical treatment; liver, kidney or metabolic diseases; uncontrolled clinical disease(such as diabetes mellitus, hypertension) or malignant tumor;
- History of severe hypersensitivity/allergy to active ingredients or any excipients of the study drug, or fluorescein and povidone iodine;
- Pregnant or lactating women or women preparing to become pregnant or breastfeeding during the study period;
- Participated in any clinical study of any other drug within 90 days of day 0, or attempted to participate in other drug trials during the study;
- Other conditions unsuitable for enrollment judged by investigatiors.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Aflibercept
only phase II
|
Aflibercept intravitreal injection given as protocol
|
Experimental: IBI302
|
IBI302(dose 1) intravitreal injection given as protocol
IBI302(dose 2) intravitreal injection given as protocol
IBI302(dose 3) intravitreal injection given as protocol
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and severity of ocular and non-ocular adverse events.
Time Frame: Up to week 20
|
To evaluate the number of subjects with ocular and non-ocular adverse events, treatment emergent adverse event, adverse event of special interest, serious adverse events; number of subjects with clinical significant abnormal laboratory values, electrocardiograms (pre and post infusions), abnormal vital signs, ophthalmic and physical examinations.
|
Up to week 20
|
DLT in each group
Time Frame: 7 days
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of BCVA from baseline by visit
Time Frame: through study completion,an average of 20 weeks
|
Best corrected visual acuity (BCVA) was measured on early treatment diabetic retinopathy study(ETDRS) chart at a starting distance of 4 meters.
The BCVAletter score ranges from 0 to 100(best score), and a gain in BCVA from baseline indicates an improvement in visual acuity.
|
through study completion,an average of 20 weeks
|
Change of CST from baseline by visit
Time Frame: through study completion,an average of 20 weeks
|
Central subfield thickness(CST) was defined as the distance between the internal limiting member and the Bruch's member using OCT, as assessed by the central reading.
|
through study completion,an average of 20 weeks
|
Area under the concentration time curve (AUC) and Maximum plasma concentration (Cmax)
Time Frame: through study completion,an average of 20 weeks
|
through study completion,an average of 20 weeks
|
|
The ADA and neutralizing antibody
Time Frame: through study completion,an average of 20 weeks
|
Blood samples were obtained for measurement of anti-drug antibodies (ADAs) to IBI302 by a validated enzyme-linked immunosorbent assay (ELISA).
|
through study completion,an average of 20 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 18, 2021
Primary Completion (Estimated)
October 31, 2023
Study Completion (Estimated)
April 30, 2024
Study Registration Dates
First Submitted
November 15, 2021
First Submitted That Met QC Criteria
July 17, 2023
First Posted (Actual)
July 27, 2023
Study Record Updates
Last Update Posted (Actual)
July 27, 2023
Last Update Submitted That Met QC Criteria
July 17, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIBI302B201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Macular Edema
-
OcugenNot yet recruitingDiabetic Macular Edema | Center Involved Diabetic Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
OculisICON plcRecruitingDiabetic Macular EdemaUnited States
-
Novartis PharmaceuticalsNot yet recruiting
-
Vista KlinikNot yet recruitingDiabetic Macular Edema
-
Chinese University of Hong KongRecruiting
-
Laboratorios Sophia S.A de C.V.RecruitingDiabetic Macular EdemaColombia, Mexico
-
Centre Hospitalier Universitaire DijonRecruiting
-
Uptown Eye SpecialistsNot yet recruitingDiabetic Macular Edema
-
Hospices Civils de LyonRecruiting
Clinical Trials on Intravitreal injection of Aflibercept
-
Indonesia UniversityBayerCompletedDiabetic Retinopathy | Diabetic Macular Edema | Clinically Significant Macular EdemaIndonesia
-
Chengdu Kanghong Biotech Co., Ltd.TerminatedNeovascular Age-related Macular DegenerationUnited States, Argentina, Australia, Austria, Belgium, Canada, Chile, Colombia, Germany, Hong Kong, Lithuania, Mexico, Netherlands, New Zealand, Peru, Philippines, Poland, Portugal, Singapore, Spain, Switzerland, Taiwan
-
Chengdu Kanghong Biotech Co., Ltd.TerminatedNeovascular Age-related Macular DegenerationUnited States, Bulgaria, China, Czechia, Denmark, France, Hungary, Israel, Italy, Latvia, Slovakia, United Kingdom
-
M. Ali Khan, MDUniversity of California, Los Angeles; Southeastern Retina Associates; Eye Associates...RecruitingProliferative Vitreoretinopathy | Retinal Detachment With Multiple Breaks, Unspecified EyeUnited States
-
Kim's Eye HospitalBayerRecruitingRetinal Angiomatous ProliferationKorea, Republic of
-
Instituto de Olhos de GoianiaUnknownChoroidal Retinal NeovascularizationBrazil
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Regeneron PharmaceuticalsCompletedNonproliferative Diabetic RetinopathyUnited States, Germany, Hungary, Japan, Puerto Rico, United Kingdom
-
Regeneron PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationUnited States
-
Regeneron PharmaceuticalsBayerCompleted